Tango Therapeutics (TNGX) Operating Leases (2020 - 2026)

Tango Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 12.21% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $30.0 million (down 12.21% YoY), while the FY2025 annual figure was $30.8 million, down 9.42% from the prior year.
• Operating Leases was $30.0 million for Q1 2026 at Tango Therapeutics, down from $30.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $39.9 million in Q3 2022 to a low of $30.0 million in Q1 2026.
• Historically, Operating Leases has averaged $35.3 million across 5 years, with a median of $35.5 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases jumped 556.05% in 2022, then slipped 12.21% in 2026.
• A 5-year view of Operating Leases shows it stood at $39.4 million in 2022, then dropped by 6.41% to $36.8 million in 2023, then dropped by 7.6% to $34.0 million in 2024, then slipped by 9.42% to $30.8 million in 2025, then slipped by 2.84% to $30.0 million in 2026.
• The last three Operating Leases figures came in at $30.0 million (Q1 2026), $30.8 million (Q4 2025), and $31.7 million (Q3 2025), per Business Quant data.